Litigation

Jazz Pharmaceuticals, Inc. et al. v. Watson Laboratories, Inc.

consolidated; resolved/terminated

14-cv-07757

Auto-generating section 1 of 5: Case overview & background…

Each section takes ~30-60s with web-search grounding. Keep this tab open — sections will fill in below as they complete.

Court: D.N.J.

Patents at issue (1)

Plaintiffs (2)

Defendants (1)

Δ Watson Laboratories, Inc.

Summary

D.N.J. Xyrem ANDA action against Watson, consolidated with the Ranbaxy and Amneal Xyrem actions for a 500 mg/ml generic sodium oxybate oral solution. The narrative identifies it among the Hatch-Waxman suits filed by Jazz on US 6,780,889; it was resolved/terminated in the 2015-2018 window.

Case overview & background

Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Key legal developments & outcome

Major rulings, motions, claim construction, settlements, and the present posture or final disposition.

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

In the news

What the press has reported about this case, summarized with links to the source articles.

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Plaintiff representatives

Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Defendant representatives

Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Record id: 6780889-14-cv-07757 · edit in Admin

Further reading

KSR International v. Teleflex (2007)
Pre-KSR, an obviousness rejection required explicit teaching, suggestion, or motivation in the prior art. Post-KSR, common sense, design needs, and predictable variations all do the work — and most patents don't survive.
Most-litigated US patents: 12 patents that defined the patent troll era
If a demand letter lands on your desk citing one of these, you are not the first. The campaign playbook is on file. The defenses other defendants used are public record.
§ 285 attorney-fee shifting in practice
§ 285 isn't a guaranteed remedy. It's a high-effort, high-evidence tool that pays off occasionally and dramatically — turning a $3M defense expense into a $3M plaintiff bill.
Non-Practicing Entity (NPE) lawsuit defense: a defendant's playbook
Defending an NPE suit is different from defending a competitor's suit. The asymmetries cut both ways — and the right plays exploit the ones that favor the defendant.
Bilski v. Kappos (2010)
Machine-or-transformation isn't the only § 101 test, business-method patents survived as a category, and the specific Bilski hedging method was unpatentable. The trio of Bilski, Mayo, and Alice gave defendants the modern § 101 motion.

All resources →